share_log

Elevai Labs | 8-K: Current report

Elevai Labs | 8-K: Current report

Elevai Labs | 8-K:重大事件
美股SEC公告 ·  2024/11/27 22:03

Moomoo AI 已提取核心信息

Elevai Labs has executed a 1-for-200 reverse stock split of its common stock effective November 27, 2024. The split was initially approved by the Board of Directors on July 23, 2024, and received stockholder approval on August 12, 2024, with the final ratio determined by the CEO on November 20, 2024.The company's common stock began trading on a split-adjusted basis on The Nasdaq Capital Market on November 27, 2024, retaining the trading symbol "ELAB" but under a new CUSIP number (28622K 203). No fractional shares were issued, with stockholders entitled to receive one whole share in lieu of fractional shares.The split had no effect on the stock's par value of $0.0001. The company has adjusted its equity incentive plan, including the number of shares available for future grants, outstanding awards, and exercise prices of stock options to reflect the split's effects.
Elevai Labs has executed a 1-for-200 reverse stock split of its common stock effective November 27, 2024. The split was initially approved by the Board of Directors on July 23, 2024, and received stockholder approval on August 12, 2024, with the final ratio determined by the CEO on November 20, 2024.The company's common stock began trading on a split-adjusted basis on The Nasdaq Capital Market on November 27, 2024, retaining the trading symbol "ELAB" but under a new CUSIP number (28622K 203). No fractional shares were issued, with stockholders entitled to receive one whole share in lieu of fractional shares.The split had no effect on the stock's par value of $0.0001. The company has adjusted its equity incentive plan, including the number of shares available for future grants, outstanding awards, and exercise prices of stock options to reflect the split's effects.
Elevai Labs于2024年11月27日执行了一次1对200的反向股票拆分。该拆分最初于2024年7月23日得到了董事会的批准,并于2024年8月12日获得了股东的批准,最终比例由首席执行官于2024年11月20日确定。公司的普通股于2024年11月27日在纳斯达克资本市场开始以拆分调整后的基础交易,保留交易标的为"ELAB",但采用新的CUSIP编号(2862.2万 203)。没有发行碎股,股东有权以整股替代碎股。该拆分对股票的面值$0.0001没有影响。公司已调整其股权激励计划,包括未来授予的可用股份数量、未偿还奖励和股票期权的行权价格,以反映该拆分的影响。
Elevai Labs于2024年11月27日执行了一次1对200的反向股票拆分。该拆分最初于2024年7月23日得到了董事会的批准,并于2024年8月12日获得了股东的批准,最终比例由首席执行官于2024年11月20日确定。公司的普通股于2024年11月27日在纳斯达克资本市场开始以拆分调整后的基础交易,保留交易标的为"ELAB",但采用新的CUSIP编号(2862.2万 203)。没有发行碎股,股东有权以整股替代碎股。该拆分对股票的面值$0.0001没有影响。公司已调整其股权激励计划,包括未来授予的可用股份数量、未偿还奖励和股票期权的行权价格,以反映该拆分的影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息